A recent analysis from the HOVON and SAKK clinical trials (HO42A, HO102, HO132 AML) demonstrated that MAC reduced relapse rates and improved overall survival in FLT3-ITD MRD AML patients compared to those receiving RIC, with similar non-relapse mortality rates between groups [59]. The gene discussed is FLT3; the disease is acute myeloid leukemia.